Bristol Myers Squibb earns long-awaited FDA nod for liso-cel, joining short list of lymphoma CAR-T winners
When Bristol Myers Squibb bought out Celgene for $74 billion back in late 2019, one of the purported centerpieces in that deal was liso-cel, which hoped to join a small group of CAR-Ts for non-Hodgkin lymphoma. Expecting an approval in 2020, Bristol has had its share of setbacks in getting liso-cel across the finish line — but now it finally has the green light.
The FDA on Friday approved Bristol’s Breyanzi (lisocabtagene maraleucel), a CAR-T to treat diffuse large B cell lymphoma in patients who have previously received two prior rounds of systemic therapy, the agency said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.